Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma

Omer Bayrak, Haluk Sen, Ersan Bulut, Beyhan Cengiz, Metin Karakok, Sakip Erturhan, Ilker Seckiner

Abstract


A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to identify patients who might respond to EGFR-targeted therapy. The aim of this study was to investigate the mutation status of EGFR, KRAS and BRAF in RCC patients. Renal tumors and normal renal samples from forty-eight patients who underwent radical or partial nephrectomy for kidney cancer were used in this study. Histological classification of the tumors was performed according to International Union against Cancer (UICC) / American Joint Committee on Cancer (AJCC) classification. Seventeen patients (48%) had clear-cell RCC, 7 (20%) had chromophobe RCC, and 11 patients (32%) had papillary RCC. DNA isolated from the samples was subjected to melting curve mutation analysis for EGFR, BRAF and KRAS using ABI-3130 DNA sequencer. DNA sequencing analysis of RCC samples, when compared with morphologically normal matched regions, did not show any exon mutations. Our results do not support the notion that EGFR, KRAS and BRAF might be mutated in RCC.


Keywords


BRAF; EGFR; KRAS; mutations

Full Text:

HTML PDF


DOI: http://dx.doi.org/10.15586/jkcvhl.2014.10

Article Metrics

Metrics Loading ...




Copyright (c) 2015 Omer Bayrak, Haluk Sen, Ersan Bulut, Beyhan Cengiz, Metin Karakok, Sakip Erturhan, Ilker Seckiner

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.